Neurogastrx, Inc.
- Industry
- Pharmaceutical Manufacturing
- Founded Year
- 2012
- Headquarters
- 500 Unicorn Park Dr, Suite 300, Woburn, Massachusetts 01801, United States
- Employee Count
- 15
Key People
- James O'Mara - President and CEO
- Jim DeTore - Chief Financial Officer
- Christophe Arbet-Engels, MD, PhD - Chief Medical Officer
- Paul Rogers - Chief Commercial Officer
- Cyril De Colle, PhD - Founder and Chief Scientific Officer
- Pankaj Pasricha, MD - Co-Founder
- Klaus Veitinger - Chairman of the Board
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises seasoned professionals with extensive experience in the pharmaceutical and biotech industries.
The leadership includes individuals like James O'Mara, who has a strong background in the industry, and other executives with significant experience in developing and commercializing GI therapies.
- Clinical Need
-
Aspect: Very Strong
Summary: Neurogastrx addresses significant unmet needs in gastrointestinal disorders.
Erosive esophagitis affects a substantial portion of GERD patients, and gastroparesis impacts millions, highlighting the critical need for innovative therapies in these areas.
- Competition
-
Aspect: Very crowded + Strategics
Summary: The gastrointestinal therapeutics market is highly competitive with numerous established players.
The market includes well-established drugs and companies, making it challenging for new entrants to gain significant market share without clear differentiators.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing therapies for GI disorders presents moderate technical challenges.
The development of GI therapies involves understanding complex pathophysiology and ensuring drug efficacy and safety, which are manageable with the right expertise.
- Patent
-
Aspect: Strong
Summary: Neurogastrx has secured strong patent protection for its pipeline.
Strong patents provide a barrier to entry for competitors and can be a valuable asset in partnerships or acquisitions.
- Financing
-
Aspect: Well-funded
Summary: The company has successfully raised significant funding to support its development programs.
The substantial funding from reputable investors provides the necessary resources to advance clinical programs and operations.
- Regulatory
-
Aspect: Pivotal Trial
Summary: Neurogastrx is progressing through pivotal trials for its lead candidates.
Success in pivotal trials is essential for regulatory approval and subsequent commercialization, making this a crucial phase for the company.
Opportunity Rollup
- Odds of Success
- 3.95
- Peak Market Share
- 5.45
- Segment CAGR
- 4.0%
- Market Segment
- Gastrointestinal Therapeutics
- Market Sub Segment
- Erosive Esophagitis and Gastroparesis Treatments
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.27 |
| 2 | 0.82 |
| 3 | 1.91 |
| 4 | 3.82 |
| 5 | 5.45 |
Key Takeaway
Neurogastrx, with its experienced team and strong financial backing, is well-positioned to address unmet needs in GI disorders, though it faces significant competition in a crowded market.